23:59 , Aug 14, 2019 |  BC Extra  |  Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

Myriad falls on sales forecast, GeneSight concerns  Myriad Genetics Inc. (NASDAQ:MYGN) tumbled $19.05 (43%) to $25.50 Wednesday, the day after the molecular diagnostics maker reported 4Q revenues of $215 million, below FactSet’s consensus of $222...
02:14 , Aug 10, 2019 |  BioCentury  |  Product Development

Payers’ view of reimbursement when gene therapy isn’t enough

Spinal muscular atrophy is giving payers a new conundrum, and the indication is poised to become a testing ground with implications for many if not all gene therapies. The issue is whether, and how, payers...
03:18 , Aug 2, 2019 |  BC Innovations  |  Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
22:54 , Aug 1, 2019 |  BC Innovations  |  Product Development

NeuBase takes antisense oligos to more targets in more places

Newcomer NeuBase Therapeutics is re-engineering antisense oligos to access a broader range of targets, while simultaneously solving the modality’s dosing and delivery issues. With three approvals since the start of 2016, antisense oligonucleotides (ASOs) have...
23:54 , Jul 26, 2019 |  BioCentury  |  Product Development

Takeda's deals paint a picture of a turnaround in action

With a spate of new and expanded deals this year, Takeda is not letting its $62 billion dollar takeout of Shire slow its transformation from a traditional small molecule company to a home for edgier,...
21:56 , Jul 23, 2019 |  BC Extra  |  Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

Biogen will increasingly prioritize immunology and ophthalmology to better balance risk and reward within its pipeline, executives said during the company's quarterly call Tuesday. As the biotech reported earnings that generally beat expectations, management played...
21:38 , Jul 23, 2019 |  BC Extra  |  Politics & Policy

How NICE is retooling the way antibiotics are valued

The U.K.'s NICE is creating a new forward-looking way to evaluate how antimicrobials will be valued. The agency's forthcoming adapted value assessment framework will aim to capture the full benefits of these agents, including their...
21:14 , Jul 8, 2019 |  BC Extra  |  Financial News

Why Medicxi invested in Evotec’s DNA damage repair spinout

The opportunity to get into the DNA damage repair space was enough for Medicxi to bend its asset-centric rule and lead the €30 million ($33.7 million) series A round for Evotec spinout Breakpoint. Medicxi's Jon...
12:50 , Jul 2, 2019 |  BC Extra  |  Politics & Policy

FDA rebuffs allegations that it has deprioritized enforcement

FDA is pushing back against assertions made in Science that a decline in the overall number of warning letters during the Trump administration is the result of a politically motivated, deregulatory agenda. The article states...
23:26 , Jun 28, 2019 |  BC Extra  |  Preclinical News

OncoSec jumps into TNBC CAR T therapy via Dana-Farber deal

By partnering with a Dana-Farber antibody engineering expert and leveraging the institute’s cell manufacturing capabilities, cytokine therapeutics company OncoSec is expanding into CAR T cell therapies for solid tumors. The deal highlights how manufacturing-savvy academic...